The company offloaded 3.75 million shares at $12 each, opting for an upsized offering that exceeded its initial plan to sell 3.3 million shares. Despite pricing at the midpoint of its projected $11 to $13 range, investor appetite proved insufficient to sustain the valuation. This sharp decline reflects broader volatility facing biopharmaceutical entrants as they transition to the public market.
Retension Pharmaceuticals Stumbles in Public Market Debut
Shares of Falls Church-based Retension Pharmaceuticals tumbled nearly 14 percent during their first day of trading, casting a shadow over an upsized initial public offering. The clinical-stage firm saw its stock price slide to $10.36 shortly after opening at $10, failing to maintain the momentum of its market entry.
Comments (0)
No comments yet. Be the first!